BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32433559)

  • 21. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
    Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia.
    Yiau SK; Lee C; Mohd Tohit ER; Chang KM; Abdullah M
    J Recept Signal Transduct Res; 2019 Jun; 39(3):276-282. PubMed ID: 31509041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
    Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
    Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin.
    Bollaert E; Claus M; Vandewalle V; Lenglez S; Essaghir A; Demoulin JB; Havelange V
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.
    Costello RT; Mallet F; Gaugler B; Sainty D; Arnoulet C; Gastaut JA; Olive D
    Cancer Res; 2000 Aug; 60(16):4403-11. PubMed ID: 10969785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
    Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
    Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
    Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
    Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
    Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
    Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
    Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
    Vandewalle V; Essaghir A; Bollaert E; Lenglez S; Graux C; Schoemans H; Saussoy P; Michaux L; Valk PJM; Demoulin JB; Havelange V
    J Cell Mol Med; 2021 Jan; 25(1):575-585. PubMed ID: 33270982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
    Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
    Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.